Home  |  Contact

Cellosaurus VAL (CVCL_1819)

[Text version]

Cell line name VAL
Accession CVCL_1819
Resource Identification Initiative To cite this cell line use: VAL (RRID:CVCL_1819)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Doubling time: ~50-70 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Transcriptome analysis.
Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia.
Derived from sampling site: Bone marrow.
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North0
East Asian, South0.47
South Asian2.83
European, North64.59
European, South32.11
Disease Diffuse large B-cell lymphoma (NCIt: C8851)
Diffuse large B-cell lymphoma (ORDO: Orphanet_544)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ

Markers:
AmelogeninX
CSF1PO10,12
D5S81811
D7S82010
D13S31710,14
D16S5399,13
TH016,9
TPOX8
vWA14,15

Run an STR similarity search on this cell line
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=8220427; DOI=10.1038/ng0993-66
Kerckaert J.-P., Deweindt C., Tilly H., Quief S., Lecocq G., Bastard C.
LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas.
Nat. Genet. 5:66-70(1993)

PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996)

PubMed=16960149; DOI=10.1182/blood-2006-06-026500
Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.-J., Wheat L.M., Karran E.L., Garcia J.F., Sanchez L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S., Martinez-Climent J.A.
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
Blood 109:271-280(2007)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767-904767(2010)

PubMed=26727417; DOI=10.3109/10428194.2015.1108414
Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Leuk. Lymphoma 57:1015-1020(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

Cross-references
Cell line collections DSMZ; ACC-586
Cell line databases/resources CCLE; VAL_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cell_Model_Passport; SIDM00416
Cosmic-CLP; 1331048
DepMap; ACH-001703
LINCS_LDP; LCL-1915
Lonza; 1237
Biological sample resources BioSample; SAMN03473489
Chemistry resources GDSC; 1331048
PharmacoDB; VAL_1652_2019
Gene expression databases ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM115973
GEO; GSM201349
GEO; GSM1035309
GEO; GSM1670570
Other Wikidata; Q54992842
Polymorphism and mutation databases Cosmic; 1086346
Cosmic; 1517631
Cosmic; 1541908
Cosmic; 2276320
Cosmic; 2297002
Entry history
Entry creation04-Apr-2012
Last entry update12-Mar-2020
Version number26